Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F-C Bidard

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2013
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancerS T Ligthart, F-C Bidard, C Decraene, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 8, 2012
Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinomaC Ngô, D Mouttet, Y De Rycke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR studyT André, C Tournigand, L Mineur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2009
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 studyF-C Bidard, C Tournigand, T André, et al.
Cancer Letters|February 22, 2015
Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trialC Helissey, F Berger, P Cottu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2010
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapyF-C Bidard, C Mathiot, A Degeorges, et al.
Bulletin Du Cancer|February 13, 2009
[Circulating tumor cells and breast cancer: detection techniques and clinical results]F-C Bidard, A-E Saliba, L Saias, et al.
Journal of Neuro-Oncology|September 18, 2013
Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepaA Comte, W Jdid, M N Guilhaume, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2009
Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancerF-C Bidard, Y M Kirova, A Vincent-Salomon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2013
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trialF C Bidard, F Huguet, C Louvet, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 2013
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancerS T Ligthart, F-C Bidard, C Decraene, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 8, 2012
Validation over time of a nomogram including HER2 status to predict the sentinel node positivity in early breast carcinomaC Ngô, D Mouttet, Y De Rycke, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2006
Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR studyT André, C Tournigand, L Mineur, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 21, 2009
Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 studyF-C Bidard, C Tournigand, T André, et al.
Cancer Letters|February 22, 2015
Circulating tumor cell thresholds and survival scores in advanced metastatic breast cancer: the observational step of the CirCe01 phase III trialC Helissey, F Berger, P Cottu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 18, 2010
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapyF-C Bidard, C Mathiot, A Degeorges, et al.
Bulletin Du Cancer|February 13, 2009
[Circulating tumor cells and breast cancer: detection techniques and clinical results]F-C Bidard, A-E Saliba, L Saias, et al.
Journal of Neuro-Oncology|September 18, 2013
Survival of breast cancer patients with meningeal carcinomatosis treated by intrathecal thiotepaA Comte, W Jdid, M N Guilhaume, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 27, 2009
Disseminated tumor cells and the risk of locoregional recurrence in nonmetastatic breast cancerF-C Bidard, Y M Kirova, A Vincent-Salomon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2013
Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trialF C Bidard, F Huguet, C Louvet, et al.
Pageof 5